1.. Introduction {#s1}
================

Inflammatory bowel diseases \[IBD\] are characterised by a chronic relapsing-remittent gastrointestinal inflammation, which is most often restricted to the colon in ulcerative colitis \[UC\] but it may involve the entire gastrointestinal tract in Crohn's disease \[CD\]. Inflammation initiation and progression is thought to be driven by a dysregulated response of the immune system, and in particular of T cells, to the intestinal microbiota or other environmental factors in genetically susceptible individuals. IBD is therefore a complex, multifactorial disease affected by immunological, environmental, and genetic components.^[@CIT0001]^

Activation of T cells by specific antigens is mediated by the interaction of their hypervariable T cell receptor \[TCR\] with the peptide-loaded major histocompatibility complex \[pMHC\] \[[Figure 1A](#F1){ref-type="fig"}\]. The MHC is encoded in humans by the human leukocyte antigen \[HLA\] complex on chromosome *6p21*.

![Interaction between an antigen presenting cell \[APC\] and a T cell, and V\[D\]J recombination, from Rosati *et al.* 2017. ^[@CIT0012]^ \[A\] Interaction between the antigen--major histocompatibility complex \[MHC\] and the αβ T cell receptor \[TCR\]. \[B\] V\[D\]J recombination: During T cell development, the loci that encode T cell receptor α and β-chains are rearranged. For both loci, variable \[V\] and joining \[J\] gene segments, and an additional diversity \[D\] gene segment for the β-chain, are recombined to form the final rearranged TCR DNA sequence. This process also involves the deletion and insertion of nucleotides at the V-D, D-J, and V-J junctions \[not shown\]. Following transcription, the sequence between the recombined V\[D\]J regions and the gene encoding the constant \[C\] region is removed by splicing. The complementarity-determining region \[CDR\] 3 is encoded by the V\[D\]J junction, whereas the CDR1 and CDR2 loops are encoded within the germline V gene. V\[D\]J, variable diversity joining; TCR, T cell receptor.](jjz179f0001){#F1}

Activated helper T cell subpopulations produce proinflammatory cytokines and are suspected to be the main drivers of inflammation in IBD.^[@CIT0002]^ The TCR protein directly interacts with the antigens, mainly through its complementarity-determining region 3 \[CDR3\]. This region is characterised by great variability, acquired through the variable diversity joining \[VDJ\] recombination process undergone during T cell development in the thymus \[[Figure 1B](#F1){ref-type="fig"}\].^[@CIT0003],[@CIT0004]^ Throughout this manuscript we will refer to each unique CDR3 sequence, generated by a specific set of variable \[V\], diversity \[D\], and joining \[J\] genes of either the α \[encoded on chromosome *14q11*\] or the β chain \[encoded on chromosome *7q34*\] of the TCR, with the term TCRα or TCRβ clonotype, respectively.

The TCR repertoire, defined as the collection of different clonotypes of an individual, is known to be altered in a series of diseases, including cancer and infectious, autoimmune, and inflammatory diseases.^[@CIT0005]^ Specifically, previous analyses of the TCR repertoire in IBD have shown repertoire alterations, and have aimed at identifying disease-associated traits and clonotypes.^[@CIT0006]^ However, until the advent of next-generation sequencing technologies, technical limitations have prevented a comprehensive TCR repertoire analysis.^[@CIT0011],[@CIT0012]^ Only recently, Chapman *et al*. published an article on the TCR repertoire in CD patients and compared the repertoire of blood and intestinal biopsies, identifying some disease-associated repertoire traits \[i.e., gene usage\] and at least one disease-associated clonotype.^[@CIT0013]^ Also, Doorenspleet and colleagues analysed the intestinal repertoire of Crohn's disease patients and controls^[@CIT0014]^ and observed that T cell clones were more expanded in Crohn's disease patients. By analysing the repertoire changes in response to therapy, the authors observed larger repertoire changes in individuals responding to therapy. However, specific disease-associated clonotypes could not be identified. Another related work was recently published by Allez *et al.*^[@CIT0015]^ These studies represent a step towards the understanding of repertoire changes in IBD. However, interindividual repertoire variability coupled with multifactorial disease complexity make identification of disease traits extremely difficult in the absence of large sample numbers. For this reason, we aimed at identifying disease-associated traits in IBD patients' blood by using a cohort of genetically matched individuals, such as monozygotic \[MZ\] twins. The analysis of MZ twins helps to reduce the degree of complexity of the study, both on the genetic---MZ twins are genetically identical^[@CIT0016]^---and the environmental levels, as the majority of the twins grew up in the same environment.^[@CIT0017]^

In the current study, we deeply profiled the α and β TCR repertoire of circulating T cells of 28 MZ twin pairs: nine German twin pairs, concordant \[*n* = 4\] and discordant \[*n* = 5\] for IBD, and 19 Danish twin pairs, discordant for IBD \[[Figure 2A](#F2){ref-type="fig"}\]. For a comparison with healthy twins, we added previously published data of three healthy Russian MZ twins to our analysis.^[@CIT0018]^ We were able to confirm previous findings regarding the TCR repertoire similarity in MZ twins, and then aimed at analysing if and how the repertoire differs in individuals with IBD. Additionally, we aimed at identifying repertoire-related disease markers by comparing the TCR repertoire of healthy and affected individuals in discordant twin pairs.

![Sample panel overview. Twin pair descriptions. In IBD-discordant twin pairs, twin number 1 is always the IBD one and twin number 2 is the healthy one in the pair. IBD, inflammatory bowel disease.](jjz179f0002){#F2}

Indeed, we observed differences in IBD-discordant twin pairs. Particularly, individuals with active disease showed decreased repertoire sharing compared with individuals with inactive disease and with healthy individuals. Additionally, we identified specific TCRs at higher (or lower) frequency in IBD patients compared with their healthy twins. Finally, we observed that smoking seems to have an effect on the peripheral TCR repertoire too and in particular smokers seem to share less clonotypes compared with non-smokers.

2.. Methods {#s2}
===========

2.1.. Sample collection and ethics statement {#s3}
--------------------------------------------

German monozygotic twin pairs sequenced in this study were recruited as a part of the sample panel described in Spehlmann *et al.*^[@CIT0017]^ Danish twin pairs were part of the twin cohort described in Moller *et al.*^[@CIT0019]^ The study setup was approved by the Bioethical Committees of the University of Kiel and the Ethics Committee of the Region of Southern Denmark \[S20120176\], respectively. All patients gave written informed consent before data and biomaterials were collected. Basic phenotypic information is shown in [Table 1](#T1){ref-type="table"}.

For German patients, only self-reported disease activity information was available since the samples were not collected in a clinical environment. German patients were therefore defined as having signs of disease activity \[SDA\] when they did not have any disease manifestation for at least 1 year before sampling, and they were defined as having SDA when they had an acute disease manifestation at sampling time, or a maximum of 35 days before, or when their disease condition was chronically active at sampling time. For Danish twin pairs, information about C-reactive protein \[CRP\], faecal calprotectin \[FCal\] levels, the Bristol stool scale, the HarveyBradshaw Index \[HBI\] for CD patients, and the Simple Clinical Colitis Activity Index \[SCCAI\] for UC patients, was available at sampling time. Individuals that had HBI/SCCAI \<5 and FCal \<50 μg/g were considered as not having SDA and therefore to be in disease remission. All other patients had possible signs of disease activity including at least one of the following:

-   HBI \>4 for CD patients and SCCAI \>4 for UC patients

-   FCal \>50 μg/g

Demographic and clinical details of all patients are summarised in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics. The table shows the different demographic and clinical traits of the twin pairs divided by ancestry. Medians are shown with interquartile range in brackets.

  Ancestry                                          Danish             German          Russian
  ------------------------------------------------- ------------------ --------------- ---------------
  **Pair type**                                     **IBD**            **IBD**         **Healthy**
  *N* pairs                                         19                 9               3
  Of which IBD concordant                           0                  4               0
  Of which IBD discordant                           19                 5               0
  Pairs with CD                                     4                  4               0
  Pairs with UC                                     15                 5               0
  Median age \[years\]                              33 \[29--40\]      34 \[33--41\]   23 \[23--24\]
  Males/females                                     11/8               4/6             0/3
  Pairs with signs of disease activity \[SDA\] CD   2                  2               0
  Pairs with signs of disease activity \[SDA\] UC   7                  3               0
  Median HBI for CD                                 4 \[3--5.5\]       na              \-
  Median HBI for CD with SDA                        7 \[77\]           na              \-
  Median SCCAI for UC                               3 \[1--5\]         na              \-
  Median SCCAI for UC with SDA                      6 \[2--8\]         na              \-
  Median CRP                                        1.2 \[1--4.15\]    na              \-
  Median CRP for IBD with SDA                       3.3 \[1--4.7\]     na              \-
  Median FCal \[ug/g\]                              15 \[15--116.5\]   na              \-
  Median FCal \[ug/g\] for IBD with SDA             134 \[63--379\]    na              \-
  Median Bristol stool scale                        4 \[4--6\]         na              \-
  Median Bristol stool scale for IBD with SDA       5 \[3.75--7\]      na              \-

IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; SDA, signs of disease activity; na, data not available; -, not applicable; HDI, HarveyBradshaw Index; SCCAI, Simple Clinical Colitis Activity Index; CRP, C-reactive protein; FCal, faecal calprotectin.

Using PAXgene tubes \[Qiagen\], 2.5 ml of blood were drawn following the manufacturer's instructions. Samples were stored at -80°C. Total RNA was isolated using the PAXgene blood miRNA kit \[Qiagen\] with automatic isolation using the Qiacube machine; 3500 ng of total RNA were used for TCR library preparation.

2.2.. TCR library preparation and sequencing {#s4}
--------------------------------------------

Molecular-barcoded TCR complementary DNA \[cDNA\] libraries were prepared as previously described,^[@CIT0018]^ with minor modifications for both TCRα and TCRβ chains. Briefly, cDNA synthesis was performed using SMARTScribe reverse transcriptase \[Clontech, Takara\] and eight cDNA synthesis reactions per sample were performed. A unique molecular identifier \[UMI\], also containing a sample barcode of 6 nucleotides, was introduced using the template-switching effect; cDNA synthesis was carried out for 60 min at 42°C and cDNA was then treated with Uracil DNA-Glycosylase \[UDG, from New England Biolabs\] and incubated for 30 min at 37°C. Samples were subsequently purified with the QIAquick PCR purification kit \[Qiagen\] and eluted in 100 µl H~2~O. Purified cDNA was then amplified with two consecutive nested PCRs, respectively 16 and 9 cycles, with purification after each PCR using MagSi-NGSprep Plus beads \[MagnaMedics\]. Illumina TruSeq compatible adapters and sample-specific barcodes were added during the second PCR.

Quality and concentration of the libraries were measured with Tapestation \[Agilent\] and Qubit \[Thermo Fisher\]. Libraries were pooled using 5 ng per library and were sequenced on Illumina HiSeq2500 with a single-index Rapid Run of 2 x 100 bp. Custom sequencing primers were added to the standard Illumina primers.

2.3.. TCR data pre-processing {#s5}
-----------------------------

PCR and sequencing error correction was performed through identification and selection of unique molecular identifiers using the software MiGEC, version 1.2.6.^[@CIT0020]^ Filtered sequences were aligned to a TCR gene reference, clonotypes were identified and grouped and CDR3 sequence was identified using the software MiXCR, version 2.1.1.^[@CIT0021]^ Clonotype tables containing clonotype counts, frequencies, CDR3 nucleotide and amino acid sequence, and V\[D\]J genes were obtained and used for further analysis.

2.4.. TCR data analysis {#s6}
-----------------------

TCR gene usage, clonotype sharing, and abundance of mucosal associated invariant T cells \[MAIT\] TCRs and natural killer T cell \[NKT\] TCRs were analysed for the most abundant 1000, 10 000, and 20 000 sequences of each sample to normalise the samples \[similar to Zvyagin *et al*.^[@CIT0022]^\]. Figures in the manuscript show results for the most abundant 10 000 clonotypes. TCR gene usage was analysed by calculating the number of clonotypes using specific V and J genes in each sample. Jensen-Shannon \[JS\] divergence^[@CIT0023]^ was calculated for each possible pair of individuals in the sample panel, and median JS between IBD patients was compared with median JS between healthy controls.

Clonotype sharing was calculated as the number of clonotypes shared by two individuals, for each possible pair of individuals in the sample panel. The median number of clonotypes shared by two IBD patients was compared with the median number shared by two healthy individuals.

For analysis of differential clonotype sharing between IBD patients and healthy individuals, we calculated the number of times that each clonotype was found to be common in two individuals affected by IBD or in two healthy individuals, among the most abundant 10 000. We then checked which clonotypes were less shared by IBD patients and more shared by healthy individuals and vice versa, thus identifying candidates for which we assessed relative abundance differences between IBD patients and healthy individuals in the whole repertoire.

Additionally, the cumulative abundance of TCR sequences originating from known specific cell types (MAIT \[mucosal associated invariant T cells\] and NKT \[natural killer T cells\]) was analysed in each sample.^[@CIT0024]^

Diversity analysis was performed by downsampling to the smallest sample \[27 000 UMIs\]. The inverse Simpson index^[@CIT0028]^ was used and calculations were performed using the Vegan R package. TCR clonality was calculated as the inverse of the Shannon entropy as previously described.^[@CIT0015]^

Statistical tests were performed using the non-parametric Wilcoxon-Mann-Whitney U test or the Kruskal-Wallis test, as indicated in the text. Statistical tests assessing differences between IBD patients and healthy individuals \[gene usage, diversity, MAIT/NKT TCRs, specific clonotype abundance\] were performed on IBD-discordant twin pairs using the Mann-Whitney U test for paired data.

Multiple comparison correction was performed using the Benjamini & Hochberg method.^[@CIT0029]^ Analysis of presence/absence of specific TCRs in IBD individuals versus their healthy twins was conducted using the McNemar statistical test for paired data^[@CIT0030]^ \[on IBD-discordant twin pairs only\].

TCR sequences were searched in VDJdb^[@CIT0031]^ using the standalone VDJmatch software version 1.2.2 and allowing no mismatches, insertions, or deletions, and matching not only the CDR3 region sequence but also V and J genes.

Identification of disease-associated clonotypes was conducted using the VDJrec^[@CIT0032]^ and ALICE^[@CIT0033]^ software \[on both IBD-concordant and -discordant twin pairs\]. VDJrec uses a group of samples of interest, in this case IBD patients, to identify clonotypes that are present at a higher frequency in the group compared with what is expected by chance, following the TCR recombination probability model.^[@CIT0034]^ In our analysis, only clonotypes present in at least three patients were considered. ALICE identifies groups of clonotypes which have the same CDR3 region length and only one mismatch of difference \[called neighbour clonotypes\] and, also using TCR generation probability, estimates which clonotypes have more neighbours than expected by chance, therefore identifying groups of clonotypes expanded in response to an antigen.

Plots were produced using the ggplot2 R package in the R programming environment version 3.4.0.

2.5.. Analysis of smoking habits {#s7}
--------------------------------

Information on smoking habits was available for all of the twin pairs in our study \[[Table 2](#T2){ref-type="table"}\]. Individual twins were stratified into 'current', 'former', or 'never' smokers. An analysis distinguishing current from former smokers was attempted, but the sample size was not sufficient to run statistical tests; therefore current and former smokers were merged together to form the 'ever-smoker' group, which was compared with the 'non-smokers'. The comparison of ever-smokers versus non-smokers was conducted only on UC patients and their healthy twins, since no concordantly smoker twin pair including a CD patient was present in our sample group.

###### 

Information on smoking habits. Only twin pairs concordant for smoking habits were used in the smoking analysis. Four twin pairs were excluded because one twin was a smoker and the other was not. Only twin pairs including UC patients were used for comparisons between smokers and non-smokers \[16 pairs\] due to the lack of twin pairs including CD patients and concordant smokers.

                                     CD   UC
  ---------------------------------- ---- --------
  **Twins both smokers**             0    **5**
  **Twins both non-smokers**         4    **11**
  **Twins discordant for smoking**   2    2

UC, ulcerative colitis; CD, Crohn's disease.

Numbers in bold indicate twin pairs used in smoker VS non-smoker comparison.

3.. Results {#s8}
===========

The investigated subjects included a total of 28 pairs of monozygotic twins, four concordant and 24 discordant for IBD, either UC or CD, nine from Germany and 19 from Denmark \[[Figure 2A](#F2){ref-type="fig"}\]. Basic phenotypic information of all individuals is presented in [Table 1](#T1){ref-type="table"}. Additionally, we analysed the repertoire of three Russian healthy twin pairs previously published by Pogorelyy *et al.* in 2017.^[@CIT0018]^

3.1.. Data overview {#s9}
-------------------

On average, 151 000 unique TCRα and 181 000 unique TCRβ sequences for each individual were available for analysis, with a minimum of 22 000 and a maximum of 576 000 sequences per individual. A summary table on sequencing information is presented as [Supplementary Data 1](#sup1){ref-type="supplementary-material"}, including the number of reads, the number of UMIs used for TCR alignment, the number of sequences/UMIs used in each clonotype table, and the number of clonotypes per sample.

It was previously shown that MZ twins share specific TCR repertoire features. They share more highly abundant clonotypes compared with unrelated individuals and they have a similar VJ gene usage.^[@CIT0022]^ We were able to replicate both twin-specific traits in our dataset \[[Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\].

3.2.. Individuals affected by IBD show specific repertoire traits and differ according todisease activity {#s10}
---------------------------------------------------------------------------------------------------------

In order to identify disease-associated traits, we focused our analyses mainly on case-control comparisons within IBD-discordant twin pairs. We compared all IBD patients against their healthy twins, as well as CD and UC patients separately, in order to identify possible existing differences between the two diseases.

We found differences between individuals affected by IBD and their healthy co-twins in TCR gene usage, diversity, MAIT TCRs and clonotype sharing \[Mann-Whitney paired U test; all *p*-values are reported in figure legends\].

To this end, we investigated whether specific V genes were significantly more or less present in IBD patients compared with healthy individuals in IBD-discordant twin pairs. Particularly, we compared the number of clonotypes carrying specific genes among the most abundant clonotypes. None of the genes showed statistically significant differences after multiple comparison correction \[Mann-Whitney paired U test\]. However, among the different comparisons we made, a small number of genes showed a consistent trend of increment or decrement in individuals with IBD and particularly in those with signs of disease activity \[SDA\] \[[Supplementary Figure 2](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\]. Analyses of the Jensen-Shannon divergence^[@CIT0023]^ metric to measure gene usage similarity showed higher similarity in the TCRα V gene usage in the most abundant clonotypes of UC patients compared with healthy individuals \[[Figure 3A](#F3){ref-type="fig"}\].This difference was not statistically significant for TCRβ V genes \[[Figure 3B](#F3){ref-type="fig"}\]. Particularly, both CD and UC patients showing signs of disease activity displayed higher gene usage similarity compared with both CD and UC patients with inactive disease, and with healthy individuals, for both TCRα \[[Figure 3C](#F3){ref-type="fig"}\] and TCRβ V genes \[[Figure 3D](#F3){ref-type="fig"}\] \[Mann-Whitney U test\].

![Jensen-Shannon divergence \[JS\] for the 10 000 most abundant clonotypes. JS of healthy individuals and IBD patients divided in CD and UC patients for \[A\] TCRα \[healthy-IBD *p* = 0.11, healthy-CD *p* = 0.55, healthy-UC *p* = 0.041, CD-UC *p* = 0.34\]; and \[B\] TCRβ V gene usage \[healthy-IBD *p* = 0.8, healthy-CD *p* = 0.8, healthy-UC *p* = 0.8, CD-UC *p* = 0.8\]. In the bottom panels IBD patients are divided based on presence or absence of signs of disease activity \[SDA\] and by disease, for \[C\] TCRα \[SDAyes-SDAno *p* = 0.0002, SDAyes-healthy *p* = 1.8 x 10^-5^, SDAno-healthy *p* = 0.09, UC: SDAyes-SDAno *p* = 0.007, CD: SDAyes-SDAno *p* = 0.2\] and \[D\] TCRβ \[SDAyes-SDAno *p* = 0.0005, SDAyes-healthy *p* = 0.007, SDAno-healthy *p* = 0.019, UC: SDAyes-SDAno *p* = 0.014, CD: SDAyes-SDAno *p* = 0.4\]. Individuals showing signs of disease activity are characterised by significantly lower JS divergence particularly in TCRα V gene usage. \[\*\] *p*-value \<0.05; \[\*\*\] *p*-value \<0.005; \[\*\*\*\] *p*-value \<0.0005. IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; TCR, T cell receptor.](jjz179f0003){#F3}

When analysing repertoire diversity in IBD-discordant twins, measured by the inverse Simpson index, we observed that diversity was decreased in individuals affected by IBD, particularly for the TCRβ chain \[the difference for the TCRα chain was not significant\] \[Mann-Whitney paired U test\] \[[Figure 4](#F4){ref-type="fig"}\]. Interestingly, this diversity decrement was significantly different between individuals with and without signs of disease activity. Surprisingly, individuals with signs of disease activity had higher diversity compared with patients with inactive disease \[[Figure 4](#F4){ref-type="fig"}\]. This observation is consistent with previous findings by others, showing a decrease in peripheral TCR repertoire diversity in patients affected by localised chronic inflammation.^[@CIT0035],[@CIT0036]^

![Repertoire diversity comparison between IBD patients and their healthy twins. The plot is divided to show CD and UC patients separately \[no significant difference was found between the two groups\], as well as patients with or without signs of disease activity. TCRα \[left\] \[IBD-healthy *p* = 0.3, SDAyes-SDAno *p* = 0.5, SDAyes-healthy *p* = 0.8, SDAno-healthy *p* = 0.2, UC: SDAyes-SDAno *p* = 0.6, CD: SDAyes-SDAno *p* = 0.7\] and TCRβ \[right\] \[IBD-healthy *p* = 0.01, SDAyes-SDAno *p* = 0.04, SDAyes-healthy *p* = 0.18, SDAno-healthy *p* = 0.04, UC: SDAyes-SDAno *p* = 0.3, CD: SDAyes-SDAno *p* = 0.1\]. Diversity was assessed through the inverse Simpson diversity index, calculated on downsampled data. Diversity was decreased in IBD patients for TCRβ clonotypes and was significantly different between patients with and without signs of disease activity. \[\*\] *p*-value \<0.05. IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; TCR, T cell receptor; SDA, signs of disease activity.](jjz179f0004){#F4}

It was previously shown that MAIT and NKT cells are less abundant in the blood of IBD patients compared with healthy controls, and they were also found to be increased and activated at the inflammation site in the gut.^[@CIT0035]^

MAIT and NKT cells are characterised by a semi-invariant TCRα repertoire.^[@CIT0024],[@CIT0025]^ Using previously published MAIT and NKT TCRα sequences,^[@CIT0024]^ we assessed their abundance in our samples \[the sequences are available in [Supplementary Data 2](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\]; estimation of MAIT/NKT cell abundance based on their TCRs is available in the Supplementary Materials, available at *ECCO-JCC* online\]. We observed that MAIT TCRα sequences were reduced in twins affected by IBD compared with their healthy co-twins \[Mann-Whitney paired Utest\] \[[Supplementary Figure 3](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\]

Furthermore, the number of clonotypes shared by each pair of individuals in our sample panel was decreased for IBD patients \[Mann-Whitney U test\]. Indeed, these shared fewer clonotypes with other IBD patients and also with healthy individuals, as compared with the average number of clonotypes shared by two healthy individuals. Of note, CD patients were shown to have significantly fewer shared clonotypes with one another compared with UC patients and controls \[[Figure 5A](#F5){ref-type="fig"} and [B\]](#F5){ref-type="fig"}. Most importantly, this characteristic was far more pronounced in individuals with signs of disease activity, for both CD and UC patients, whereas in individuals with inactive disease it was more similar to that of healthy individuals \[[Figure 5C](#F5){ref-type="fig"} and [D\]](#F5){ref-type="fig"}.

![Clonotype sharing and clonotypes decreased in IBD patients. Number of shared clonotypes for each pair of IBD patients \[CD and UC\] and their healthy twins for the 10 000 most abundant clonotypes of \[A\] TCRα \[healthy-IBD *p* = 0.002, healthy-CD *p* = 0.0002, healthy-UC *p* = 0.97, CD-UC *p* = 0.0002\] and \[B\] TCRβ \[healthy-IBD *p* = 0.064, healthy-CD *p* = 0.01, healthy-UC *p* = 0.96, CD-UC *p* = 0.01\]. In the bottom panels, IBD patients are divided based on presence or absence of signs of disease activity \[SDA\] and by disease, for \[C\] TCRα \[SDAyes-SDAno *p* = 1.4 x 10^-11^, SDAyes-healthy *p* = 1.8 x 10^-8^, SDAno-healthy *p* = 0.005, UC: SDAyes-SDAno *p* = 7 x 10^-6^, CD: SDAyes-SDAno *p* = 0.1, healthy-CD:SDAyes *p* = 0.01, healthy-UC:SDAyes *p* = 0.007, SDAyes: CD-UC *p* = 0.03, SDAno: CD-UC *p* = 0.03\] and \[D\] TCRβ \[SDAyes-SDAno *p* = 1.8x10^-5^, SDAyes-healthy *p* = 0.0001, SDAno-healthy *p* = 0.15, UC: SDAyes-SDAno *p* = 0.003, CD: SDAyes-SDAno *p* = 0.38, healthy-CD:SDAyes *p* = 0.12, healthy-UC:SDAyes *p* = 0.07, SDAyes: CD-UC *p* = 0.27, SDAno: CD-UC *p* = 0.12\]. Clonotype sharing was decreased in between IBD patients and more in CD patients compared with UC patients. Particularly, individuals showing signs of disease activity were sharing less clonotypes compared with patients without signs of disease activity. Specific clonotypes whose abundance was found to be decreased in IBD patients are displayed for \[E\] TCRα \[CVVSPYSSASKIIF *p* = 0.07, CAASYSSASKIIF *p* = 0.08, CATDDNYGQNFVF *p* = 0.02, CAGSNTGNQFYF *p* = 0.08, CAASAGGATNKLIF *p* = 0.07, CAASGYGGATNKLIF *p* = 0.08, CAASEGYGGSQGNLIF *p* = 0.07, CAYRSGNSGGSNYKLTF *p* = 0.08\] and \[F\] TCRβ \[CASSFLAGTDTQYF *p* = 0.17, CASSLDTEAFF *p* = 0.055, CASSLGSGANVLTF *p* = 0.09, CASSYSVNTEAFF *p* = 0.017\] chain. \[\*\] *p*-value \<0.05; \[\*\*\] *p*-value \<0.005; \[\*\*\*\] *p*-value \<0.0005. IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; TCR, T cell receptor.](jjz179f0005){#F5}

This observation is consistent with the decrease in TCR repertoire diversity in IBD patients, as described above. Of note, in the analyses about shared clonotypes described above, differences were statistically significant not only for IBD patients \[CD and UC united\] compared with healthy individuals, but also for UC or CD patients separately. However, often results for CD patients were not significant, probably due also to the low sample size, but a clear trend was present.

Following these observations, we investigated which of the 10 000 most abundant clonotypes were shared only or mainly by healthy individuals and not by IBD patients \[in IBD-discordant twin pairs only\]. Thirty TCRα sequences were shared by at least 28 pairs of healthy individuals and one or no pairs of IBD patients, whereas 16 TCRβ sequences were shared by at least 10 pairs of healthy individuals and by one or no pairs of IBD patients. Of note, TCRα sequences are less diverse compared with TCRβ and are therefore most commonly shared interindividually. Among these thus identified clonotypes, we investigated abundance differences between IBD twins and their healthy co-twins \[Mann-Whitney paired U test\]. Results are reported in [Figure 5E](#F5){ref-type="fig"} and [F](#F5){ref-type="fig"}. In particular, 12 TCRα \[eight of which are shown in [Figure 5E](#F5){ref-type="fig"}\] and four TCRβ clonotypes showed a trend towards decreased abundance in IBD patients. This trend was significant after multiple comparison correction for one TCRα and one TCRβ sequence.

In comparison, 16 TCRα and 15 TCRβ sequences were shared most commonly among IBD patients, versus healthy individuals \[[Supplementary Data 3](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\]. Among these, seven TCRα and five TCRβ sequences seemed to be more abundant in IBD patients compared with healthy individuals, and of these seven, five TCRα sequences were significantly more abundant in IBD patients \[[Supplementary Figure 4](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\].

Interestingly, some of the clones identified to be more shared among IBD individuals compared with controls are known to be reactive to common viruses^[@CIT0031]^ \[[Supplementary Figure 4](#sup1){ref-type="supplementary-material"}; and [Table 3](#T3){ref-type="table"}\].

###### 

CDR3 sequences with known antigen reactivity. These sequences were found at higher abundance in IBD patients compared with their healthy co-twins. Column 3 lists the pathogens which they were found to be reactive to, according to VDJdb.^[@CIT0028]^ Column 4 indicates whether the V region of the antigen reactive clonotype was the same in our own data. Identical CDR3 regions with different V genes may or may not recognise the same antigen.

  CDR3 region       Chain   Antigen reactivity                                  V gene concordance with VDJdb
  ----------------- ------- --------------------------------------------------- -------------------------------
  CAVSSNDYKLSF      alpha   Influenza A,^[@CIT0039]^ yellow fever^[@CIT0040]^   No
  CAVMNYGGSQGNLIF   alpha   CMV^[@CIT0041]^                                     No
  CAVEDSNYQLIW      alpha   CMV^[@CIT0041]^                                     No
  CAASGGGSYIPTF     alpha   CMV, EBV^[@CIT0041]^                                No
  CSARDRVGNTIYF     beta    EBV^[@CIT0042]^                                     Yes
  CASSLGYEQYF       beta    CMV, EBV^[@CIT0041],[@CIT0043]^                     No
  CSVGAGGTNEKLFF    beta    EBV^[@CIT0042]^                                     Yes

IBD, inflammatory bowel disease; V\[D\]J, variable diversity joining; CMV, cytomegalovirus; EBV, EpsteinBarr virus.

3.3.. Smoking impacts on the peripheral TCR repertoire of healthy individuals and UC patients {#s11}
---------------------------------------------------------------------------------------------

A recent work from Allez and colleagues^[@CIT0015]^ showed how TCR clonality was higher in the ileum of smoking compared with non-smoking CD patients. We therefore analysed if and how smoking behaviour impacts on the peripheral TCR repertoire in our sample panel. We compared only twin pairs concordant for smoking behaviour. Therefore, we compared smoker and non-smoker UC patients but not CD patients, since no twin pair including CD patients had the same smoking habits. We did not observe significant differences between the TCR clonality and repertoire diversity of ever-smokers and non-smokers, both in healthy individuals and UC patients \[[Supplementary Figure 5](#sup1){ref-type="supplementary-material"}, available at *ECCO-JCC* online\]. We also compared gene usage similarity and clonotype sharing of smokers and non-smokers. In healthy individuals, TCRα gene usage is more similar among smokers compared with non-smokers, whereas TCRβ gene usage seems to diverge more among smokers. As previously mentioned, UC and CD patients seem to have more similar TCRα gene usage compared with healthy individuals; however this seems to be true only for non-smokers, and gene usage similarity seems to be more variable in smoker UC patients \[[Figure 6A](#F6){ref-type="fig"} and [B\]](#F6){ref-type="fig"} \[Mann_Whitney paired U test\].

![Impact of smoking behaviour on the peripheral TCR repertoire considering the 10 000 most abundant clonotypes. Smokers \[yes\] and non-smokers \[no\] are compared as well as healthy individuals and IBD patients. The Jensen-Shannon divergence between samples is depicted for \[A\] TCRα \[healthy: smokers/non-smokers *p* = 0.03, UC: smokers/non-smokers *p* = 0.22, non-smokers: UC-healthy *p* = 0.0015, non-smokers: CD-healthy *p* = 0.01, non-smokers: CD-UC *p* = 0.21, smokers: UC-healthy *p* = 0.17\] and \[B\] TCRβ \[healthy: smokers/non-smokers *p* = 0.02, UC: smokers/non-smokers *p* = 0.0003, non-smokers: UC-healthy *p* = 0.31, non-smokers: CD-healthy *p* = 0.16, non-smokers: CD-UC *p* = 0.34, smokers: UC-healthy *p* = 0.09\]. The number of shared clonotypes is shown for \[C\] TCRα \[healthy: smokers/non-smokers *p* = 0.0001, UC: smokers/non-smokers *p* = 0.007, non-smokers: UC-healthy *p* = 0.003, non-smokers: CD-healthy *p* = 0.003, non-smokers: CD-UC *p* = 0.02, smokers: UC-healthy *p* = 0.5\] and \[D\] TCRβ \[healthy: smokers/non-smokers *p* = 0.01, UC: smokers/non-smokers *p* = 0.08, non-smokers: UC-healthy *p* = 0.06, non-smokers: CD-healthy *p* = 0.02, non-smokers: CD-UC *p* = 0.19, smokers: UC-healthy *p* = 0.85\]. \[\*\] *p*-value \<0.05; \[\*\*\] *p*-value \<0.005; \[\*\*\*\] *p*-value \<0.0005. IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; TCR, T cell receptor.](jjz179f0006){#F6}

Similarly, the number of shared clonotypes is higher in non-smokers compared with smokers in healthy individuals and also in UC patients. However, whereas non-smoker IBD patients share fewer clonotypes compared with healthy individuals, this does not seem to be the case among smokers \[Mann-Whitney paired U test\] \[[Figure 6C](#F6){ref-type="fig"} and [D\]](#F6){ref-type="fig"}.

3.4.. Towards the identification of disease-associated clonotypes {#s12}
-----------------------------------------------------------------

We also wanted to investigate whether disease-associated and peripherally enriched TCRs exist in IBD patients compared with healthy individuals, and to identify them. This is a highly complex task for such multifactorial diseases that exhibit high interindividual differences, and for which the antigenic triggers are still unknown.

We therefore employed different methodologies to identify such clonotypes, using methods which were recently used for similar purposes by Komech *et al*.^[@CIT0044]^ for ankylosing spondylitis patients. VDJrec^[@CIT0032]^ and ALICE^[@CIT0033]^ are methods used for the identification of TCRβ clonotypes, which are condition-associated and involved in an active immune response, respectively. These methods are based on the TCR recombination probability model.^[@CIT0034]^ Since they identify TCRs involved in immune responses in both patients and controls, these may also include responses to common pathogens such as influenza A, Epstein-Barr virus \[EBV\], and others. We therefore re-searched our candidate disease-associated sequences in the VDJdb database^[@CIT0031]^ and were thus able to discriminate such known TCRs. To identify TCRs mostly present in IBD individuals, and not in their healthy co-twins, we used the McNemar statistical test^[@CIT0030]^ for paired data. By employing these three methods to analyse our samples, we were able to identify a series of candidate disease-associated clonotypes. Results from all methods are available in the supplementary materials \[[Supplementary Data 3](#sup1){ref-type="supplementary-material"}\].

We then analysed the results overlapping between these three methods, in more detail. During this analysis we found that only one clonotype appeared to be enriched in IBD patients. This clonotype \[CASSVRSSYEQYF, TRVB19, TRBJ2-7\] is present in VDJdb and is known to be reactive to influenzaA virus.^[@CIT0045]^ Three other clonotypes stood out in both the McNemar and ALICE analyses; however, these were enriched in healthy individuals compared with IBD patients.

Special emphasis needs to be put on the 10 clonotypes listed in [Table 4A](#T4){ref-type="table"}, since these were found to be enriched in IBD patients in both VDJrec and the McNemar test results, thus implying that these may be potentially disease-associated clonotypes. This table also includes the clonotype reactive for influenzaA mentioned above. Additionally, we have listed the clonotypes reaching the lowest *p*-value in the McNemar test for being potentially enriched in IBD patients \[[Table 4B](#T4){ref-type="table"}\]. These clonotypes were present in at least eight IBD patients, but not in their healthy co-twins, and they mainly used V genes TRBV5-1 and TRBV7-2.

###### 

Candidate disease-associated clonotypes. The table is divided into three parts. \[A\] TCRβ clonotypes which were identified as possibly disease-associated from both VDJrec and McNemar tests. \[B\] Possible disease-associated TCRβ clonotypes, top hits from McNemar test. \[C\] Possible disease-associated TCRα clonotypes, top hits from McNemar test. In addition to describing the clonotypes by their CDR3 region and V and J genes, the last four columns of the table describe the number of IBD discordant twin pairs in which these clonotypes where observed.

          CDR3 sequence      V gene        J gene    Present in both twins   Present only in IBD twin   Present only in healthy twin   Not present
  ------- ------------------ ------------- --------- ----------------------- -------------------------- ------------------------------ -------------
  **A**   CASSFVAGTDTQYF     TRBV28        TRBJ2-3   4                       6                          0                              14
          CASSLAGGDQPQHF     TRBV5-5       TRBJ1-5   0                       8                          0                              16
          CASSLDGTGPYNEQFF   TRBV7-2       TRBJ2-1   0                       6                          0                              18
          CASSLGQGGTYEQYF    TRBV7-2       TRBJ2-7   0                       6                          0                              18
          CASSPGTANSPLHF     TRBV5-1       TRBJ1-6   1                       8                          0                              15
          CASSPPGQGGEKLFF    TRBV18        TRBJ1-4   0                       8                          1                              15
          CASSPSGGRQPQHF     TRBV18        TRBJ1-5   0                       6                          0                              18
          CASSQGQGAGQPQHF    TRBV3-1       TRBJ1-5   0                       8                          1                              15
          CASSVRSSYEQYF      TRBV19        TRBJ2-7   0                       6                          0                              18
          CSARRQGGTEAFF      TRBV20-1      TRBJ1-1   1                       9                          1                              13
  **B**   CASSPGGTYEQYF      TRBV5-1       TRBJ2-7   2                       10                         0                              12
          CASSLVGGDTEAFF     TRBV5-1       TRBJ1-1   3                       9                          0                              12
          CAWSVRGNTEAFF      TRBV30        TRBJ1-1   0                       9                          0                              15
          CASSLAGGDQPQHF     TRBV5-5       TRBJ1-5   0                       8                          0                              16
          CASSLALAGGTDTQYF   TRBV5-1       TRBJ2-3   1                       8                          0                              15
          CASSLEGRSSYEQYF    TRBV5-1       TRBJ2-7   0                       8                          0                              16
          CASSLGGGTYEQYF     TRBV7-2       TRBJ2-7   1                       8                          0                              15
          CASSLSRNQPQHF      TRBV7-2       TRBJ1-5   0                       8                          0                              16
          CASSLTGNTGELFF     TRBV7-2       TRBJ2-2   1                       8                          0                              15
          CASSLVQGAYNEQFF    TRBV5-1       TRBJ2-1   1                       8                          0                              15
          CASSPGTANSPLHF     TRBV5-1       TRBJ1-6   1                       8                          0                              15
          CASSLRNTGELFF      TRBV12-3      TRBJ2-2   1                       10                         1                              12
  **C**   CAASSLTGNQFYF      TRAV13-1      TRAJ49    1                       12                         0                              11
          CALLGGTSYGKLTF     TRAV9-2       TRAJ52    4                       11                         0                              9
          CAYRSGYNNARLMF     TRAV38-2DV8   TRAJ31    0                       11                         0                              13
          CAAKNDYKLSF        TRAV13-1      TRAJ20    0                       10                         0                              14
          CAEGRDDKIIF        TRAV5         TRAJ30    0                       10                         0                              14
          CAGDGGSQGNLIF      TRAV27        TRAJ42    3                       10                         0                              11
          CALGGLTGGGNKLTF    TRAV6         TRAJ10    0                       10                         0                              14
          CAMSSQGAQKLVF      TRAV12-3      TRAJ54    4                       10                         0                              10
          CAVTPNQAGTALIF     TRAV8-1       TRAJ15    5                       10                         0                              9
          CAVTPTGGFKTIF      TRAV8-6       TRAJ9     1                       10                         0                              13
          CAYRITGNQFYF       TRAV38-2DV8   TRAJ49    11                      10                         0                              3

TCR, T cell receptor; IBD, inflammatory bowel disease; V\[D\]J, variable diversity joining

ALICE and VDJrec are currently available only for TCRβ analysis. However, we also ran the McNemar test for the TCRα chain. The clonotypes obtaining the lowest *p*-values are listed in [Table 4C](#T4){ref-type="table"}.

4.. Discussion {#s13}
==============

The TCR repertoire composition is strongly influenced by the HLA type of the individuals,^[@CIT0046],[@CIT0047]^ which should be taken into account when conducting standard case-control TCR repertoire studies. In our study design we therefore decreased the degree of complexity by comparing genetically identical individuals, making it easier to detect disease-associated traits.

By investigating the TCRα and TCRβ repertoire of the circulating lymphocytes of 28 MZ twin pairs concordant or discordant for IBD, we were able to replicate previous findings concerning the similarity in the repertoire of MZ twins and, most interestingly, we identified features associated with IBD, disease activity, and smoking habits. We also showed how the TCR repertoire of CD and UC patients differs in certain respects, such as clonotypes sharing.

We did not observe higher repertoire similarity in clonotype sharing or gene usage \[data not shown\] between twins concordant for IBD compared with twins discordant for IBD. However, this may also be due to a limited statistical power.

Our results regarding diversity, gene usage, clonotype sharing, and MAIT TCRs suggest that significant shifts occur in the peripheral TCR repertoire of IBD patients compared with healthy individuals. We observed that gene usage, particularly for TCRα chain, is more similar among UC patients compared with controls, and in both CD and UC patients showing signs of disease activity compared with healthy individuals \[[Figure 3](#F3){ref-type="fig"}\]. This higher gene usage similarity did not translate into a higher number of shared clonotypes between patients. On the contrary, patients shared fewer clonotypes compared with healthy individuals. This effect was stronger for CD patients and patients showing signs of disease activity \[[Figure 5](#F5){ref-type="fig"}\]. Additionally, repertoire diversity and MAIT TCRs were decreased in IBD patients \[[Figure 4](#F4){ref-type="fig"}; and [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}\]. These findings suggest that clonotypes normally present in the blood of healthy individuals may be decreased or absent in the blood of IBD patients. Others^[@CIT0035],[@CIT0036],[@CIT0048]^ previously suggested that this may indicate a recruitment of certain circulating T cells to the inflammation site. However, it may also mean that different clonotypes arise in the peripheral repertoire of IBD patients. These two possible explanations are not mutually exclusive, and analyses of matched inflamed intestinal tissue and peripheral blood TCR repertoire will be necessary to better understand the dynamic of TCR repertoire changes in the blood and intestine of IBD patients.

We also analysed the impact of smoking habits on the peripheral TCR repertoire, and found that smokers shared fewer clonotypes compared with non-smokers, in both health and disease. Interestingly, although IBD patients showed lower gene usage divergence and clonotypes sharing compared with healthy individuals in the non-smoking group, this finding did not hold true among smokers \[[Figure 6](#F6){ref-type="fig"}\]. Among smokers, we only analysed UC patients and their healthy twins, as we lacked CD patients in the smoker group. We did not observe higher TCR clonality in smoker patients compared with controls, as previously shown by Allez and colleagues.^[@CIT0015]^ However, our analysis was limited to the peripheral blood. Additionally, smoking is known to have different effects in CD and UC,^[@CIT0049]^ and therefore we cannot exclude that these may reflect on differences in the TCR repertoire, too. Both smoking and signs of IBD activity seem to lead to a lower number of shared clonotypes. These effects seem to be unrelated, since: \[i\] decrease in shared clonotypes was observed in healthy individuals who smoke and not only in patients; and \[ii\] only two patients among those showing signs of disease activity were smokers, and therefore there is a very small overlap between the two groups. It was shown that smoking leads to the relative increase of specific T cell populations in the blood,^[@CIT0050]^ which may explain the decrease in clonotypes sharing between individuals. Simultaneously, smokers are exposed to a higher number of aero-antigens capable of triggering the immune system. This may potentially lead to the presence of different T cell clonotypes in the blood of smokers, which are not found in non-smokers.

In addition to investigating disease-associated repertoire traits, we also aimed at identifying specific candidate disease-associated clonotypes. We identified clonotypes with decreased or increased abundance in IBD patients' blood. Most interestingly, one of the TCRβ sequences showing lower abundance in IBD patients' blood \[CASSLGSGANVLTF\] was previously identified by Henriksen *et al*.^[@CIT0051]^ to be specific for primary sclerosing cholangitis \[PSC\]. This sequence was found to be enriched in the liver of PSC patients and in the liver and gut of PSC-IBD patients, as compared with colorectal cancer \[CRC\] tissue. Since in this study the authors did not analyse blood from CRC patients, it is possible that this clonotype is normally present in the blood of healthy individuals, and that cells expressing this clonotype are recruited to the inflammation site in patients affected by chronic inflammatory conditions, therefore decreasing their relative frequency in the peripheral blood, as shown in our data.

In order to identify clonotypes enriched in IBD patients, we used different methodologies and analysed the best hits overlapping in all methods. We identified a number of clonotypes which seem to be enriched in IBD individuals, as compared with their healthy co-twins. The only clonotype \[CASSVRSSYEQYF\] that stood out, in the results of all three methods we used, was found to be reactive to influenza A. Interestingly, some of the clones identified to be more shared among IBD individuals compared with controls are known to be reactive to common viruses^[@CIT0031]^ \[[Supplementary Figure 4](#sup1){ref-type="supplementary-material"}; and [Table 3](#T3){ref-type="table"}\]. For example, it is known that IBD patients have an increased risk of developing influenza.^[@CIT0052]^ Therefore, they may also have more influenza-reactive T cells compared with controls. IBD patients' higher risk of contracting or reactivating viral infections, also due to immunosuppressive treatment (as for EBV^[@CIT0053]^ and ^cytomegalovirus\ \[^CMV\]^[@CIT0054]^), may be a possible explanation for the enrichment of these TCRs in IBD patients. However, it is important to keep in mind that TCRs are cross-reactive against different antigens. It is thus likely that these clonotypes are also reactive to other antigens that could be associated with IBD onset and/or progression. Also, TCRβ alone is not sufficient to define antigen specificity, which may differ depending on the employed TCRα chain and CD4/CD8 molecules.

Our findings do not seem to support the existence of a single strong signal or clonotype associated with IBD. Indeed, IBD is a highly complex disease, characterised by strong interindividual variability which is partly attributed to genetic differences, and for which the existence of a single antigenic trigger has not been demonstrated yet. Moreover different disease treatments, which often involve immunosuppressive drugs, may differently impact on the repertoire of the patients, potentially increasing the background noise of the data and the interindividual variability. Also, we were not able to distinguish between different T cell subtypes in our analysis. Taking these limitations into account, our TCR repertoire results, like others before us,^13,\ 15,55^ rather seem to support the existence of multiple different antigens that trigger the response of different T cell clonotypes. Based on these considerations and on our results, we suggest that the search for disease-associated clonotypes \[and indirectly antigens\] should be conducted in selected patient subgroups matched, for example, by HLA type, medical treatment, or other meaningful clinical traits.

Even though the number of samples in our study may seem limited compared with huge genetics studies, our sample panel is the largest among TCR repertoire studies in twins. Repeated sampling of the same and of other genetically matched individuals may help to strengthen the findings and identify stronger signals.

We will replicate our findings and identify additional disease-associated traits in a large case-control sample collection, and will validate signatures observed in blood by comparing matched blood and intestinal TCR repertoires.

In conclusion, we think that TCR repertoire disease-associated traits and clonotypes may have the potential to be used as diagnostic or therapy response markers. Our results, showing differences not only between IBD and healthy twins but also between patients with and without signs of disease activity, represent, together with works by others,^[@CIT0015]^ a first step towards this goal.

Supplementary Material
======================

###### 

Click here for additional data file.
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